163 related articles for article (PubMed ID: 15717632)
21. Staff-assisted nursing home haemodialysis: patient characteristics and outcomes.
Reddy NC; Korbet SM; Wozniak JA; Floramo SL; Lewis EJ
Nephrol Dial Transplant; 2007 May; 22(5):1399-406. PubMed ID: 17259652
[TBL] [Abstract][Full Text] [Related]
22. Cerebrovascular disease in maintenance hemodialysis patients: results of the HEMO Study.
Delmez JA; Yan G; Bailey J; Beck GJ; Beddhu S; Cheung AK; Kaysen GA; Levey AS; Sarnak MJ; Schwab SJ;
Am J Kidney Dis; 2006 Jan; 47(1):131-8. PubMed ID: 16377394
[TBL] [Abstract][Full Text] [Related]
23. Salivary beta2-microglobulin analysis in chronic kidney disease and hemodialyzed patients.
Michelis R; Sela S; Ben-Zvi I; Nagler RM
Blood Purif; 2007; 25(5-6):505-9. PubMed ID: 18187941
[TBL] [Abstract][Full Text] [Related]
24. Acute effect of low-flux hemodialysis process on the results of the interferon-gamma-based QuantiFERON-TB Gold In-Tube test in end-stage renal disease patients.
Hursitoglu M; Cikrikcioglu MA; Tukek T; Beycan I; Ahmedova N; Karacuha S; Sansal M; Ozkan O; Celik V
Transpl Infect Dis; 2009 Feb; 11(1):28-32. PubMed ID: 18803615
[TBL] [Abstract][Full Text] [Related]
25. Pre-dilution on-line haemofiltration vs low-flux haemodialysis: a randomized prospective study.
Beerenhout CH; Luik AJ; Jeuken-Mertens SG; Bekers O; Menheere P; Hover L; Klaassen L; van der Sande FM; Cheriex EC; Meert N; Leunissen KM; Kooman JP
Nephrol Dial Transplant; 2005 Jun; 20(6):1155-63. PubMed ID: 15784639
[TBL] [Abstract][Full Text] [Related]
26. Expression of beta2-microglobulin and c-fos mRNA: is there an influence of high- or low-flux dialyzer membranes?
Haufe CC; Eismann U; Deppisch RM; Stein G
Kidney Int Suppl; 2001 Feb; 78():S177-81. PubMed ID: 11169006
[TBL] [Abstract][Full Text] [Related]
27. A new synthetic dialyzer with advanced permselectivity for enhanced low-molecular weight protein removal.
Krieter DH; Lemke HD; Wanner C
Artif Organs; 2008 Jul; 32(7):547-54. PubMed ID: 18638309
[TBL] [Abstract][Full Text] [Related]
28. The prevalence of insulin resistance and its relationship between anemia, secondary hyperparathyroidism, inflammation, and cardiac parameters in chronic hemodialysis patients.
Sit D; Kadiroglu AK; Yilmaz ME; Kara IH; Isikoglu B
Ren Fail; 2005; 27(4):403-7. PubMed ID: 16060127
[TBL] [Abstract][Full Text] [Related]
29. Clinical outcomes for maintenance hemodialysis patients using a high-flux (FX60) dialyzer.
Li Y; Wang Y; Lv J; Wang M
Ren Fail; 2013 Oct; 35(9):1240-5. PubMed ID: 23924354
[TBL] [Abstract][Full Text] [Related]
30. Dialysis-related amyloidosis: late finding or hidden epidemic?
Dember LM; Jaber BL
Semin Dial; 2006; 19(2):105-9. PubMed ID: 16551286
[TBL] [Abstract][Full Text] [Related]
31. [Middle molecules removal. Beyond beta2-microglobulin].
Maduell F; Sánchez-Canel JJ; Blasco JA; Navarro V; Ríus A; Torregrosa E; Pin MT; Cruz C; Ferrero JA
Nefrologia; 2006; 26(4):469-75. PubMed ID: 17058859
[TBL] [Abstract][Full Text] [Related]
32. [Effects of different dialysis membranes and techniques on the nutritional status, morbidity and mortality of hemodialysis patients].
Chiappini MG; Ammann T; Selvaggi G; Bravi M; Traietti P
G Ital Nefrol; 2004; 21 Suppl 30():S190-6. PubMed ID: 15750983
[TBL] [Abstract][Full Text] [Related]
33. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
Ross EA; Tian J; Abboud H; Hippensteel R; Melnick JZ; Pradhan RS; Williams LA; Hamm LL; Sprague SM
Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251
[TBL] [Abstract][Full Text] [Related]
34. [Changes of calcium-phosphorus metabolism in patients with chronic renal failure on hemodialysis treatment].
Pérez Ruilópez MA; Damiano Rivero A; Herrerías Echabe JM; Garrido Peralta M
Rev Iber Endocrinol; 1976; 23(138):535-55. PubMed ID: 1013577
[TBL] [Abstract][Full Text] [Related]
35. Among therapy modalities of end-stage renal disease, renal transplantation improves survival in patients with amyloidosis.
Ozdemir BH; Ozdemir FN; Sezer S; Sar A; Haberal M
Transplant Proc; 2006 Mar; 38(2):432-4. PubMed ID: 16549140
[TBL] [Abstract][Full Text] [Related]
36. Uraemic itching: do polymethylmethacrylate dialysis membranes play a role?
Aucella F; Vigilante M; Gesuete A; Maruccio G; Specchio A; Gesualdo L
Nephrol Dial Transplant; 2007 Jul; 22 Suppl 5():v8-12. PubMed ID: 17586845
[TBL] [Abstract][Full Text] [Related]
37. Paraoxonase-1 concentrations in end-stage renal disease patients increase after hemodialysis: correlation with low molecular AGE adduct clearance.
Gugliucci A; Mehlhaff K; Kinugasa E; Ogata H; Hermo R; Schulze J; Kimura S
Clin Chim Acta; 2007 Feb; 377(1-2):213-20. PubMed ID: 17118352
[TBL] [Abstract][Full Text] [Related]
38. Increased levels of serum matrix metalloproteinase-3 in haemodialysis patients with dialysis-related amyloidosis.
Naganuma T; Sugimura K; Uchida J; Tashiro K; Yoshimura R; Takemoto Y; Nakatani T
Nephrology (Carlton); 2008 Apr; 13(2):104-8. PubMed ID: 18275497
[TBL] [Abstract][Full Text] [Related]
39. Electronegative LDL and lipid abnormalities in patients undergoing hemodialysis and peritoneal dialysis.
Lobo J; Santos F; Grosso D; Lima R; Barreira AL; Leite M; Mafra D; Abdalla DS
Nephron Clin Pract; 2008; 108(4):c298-304. PubMed ID: 18434752
[TBL] [Abstract][Full Text] [Related]
40. Effect of membrane flux and dialyzer biocompatibility on survival in end-stage diabetic nephropathy.
Götz AK; Böger CA; Popal M; Banas B; Krämer BK
Nephron Clin Pract; 2008; 109(3):c154-60. PubMed ID: 18663328
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
